BioSpace News Archive

Turnstone Biologics Corp. announced financial results for the second quarter ended June 30, 2023, and provided an update on recent business highlights.

Idiopathic Pulmonary Fibrosis (IPF) is a serious chronic lung disease characterized by the thickening and stiffening of the lung tissue surrounding the air sacs.

Mitsubishi Tanabe Pharma Canada, a subsidiary of Mitsubishi Tanabe Pharma America, Inc., announced that RADICAVA® Oral Suspension is now covered under the Saskatchewan Drug Plan Formulary for the treatment of people living with amyotrophic lateral sclerosis, a rapidly progressive, neurodegenerative disease.

Florida Cancer Specialists & Research Institute, LLC Is pleased to announce that Central Florida Cancer Care Center/Radiation Oncology Consultants, PA has joined the statewide practice, effective September 1, 2023.

ANGUS Chemical Company announced the completion of its corporate rebrand and corporate name change to Advancion Corporation, effective September 1, 2023.

Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today that it raised approximately $35 million through the exercise of all the Tranche A warrants issued as part the previously announced March 29, 2023 Private Investment in Public Equity (PIPE) financing.

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

Immunocore Holdings Plc announced that management will present at the following investor conferences in September.

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today issued the following statement about the closure of COBRA, a minimum residual disease (MRD) study.

Cytokinetics, Incorporated announced that on August 31, 2023 it granted stock options to purchase an aggregate of 77,800 shares of common stock to 4 new employees, whose employment commenced in August 2023, as a material inducement to their employment.